IONpath Launches Research Services Offering Multiplexed Tissue Analysis to Empower Pharmaceutical Discovery and Development Programs

Menlo Park, Calif., February 11, 2020 – IONpath, Inc., today announces the launch of a dedicated service business providing access to their proprietary MIBIscope™ multiplexed imaging platform and its team of experts to support pharmaceutical and biotechnology companies working in immuno-oncology.

IONpath has previously provided custom research services to leading academic and pharmaceutical organizations as part of an Early Access Program. Now the company has formalized its intentions to become a partner of choice to those interrogating the tumor microenvironment to understand therapeutic mechanism of action and identify responder populations.  

“We started this company because we love doing great science and working with great scientists,” said Harris Fienberg, chief executive officer and co-founder, IONpath. “Our team is incredibly excited to enable the next generation of immunotherapy development on a massive scale.”

Based in their global headquarters in Silicon Valley and serving clients from around the world, an expert team of engineers, pathologists and data scientists are leveraging the proprietary MIBIscope platform to help solve the most complex problems in immuno-oncology.  The MIBIscope™ can simultaneously image forty or more individual proteins on a single slide with the reproducibility needed for large clinical studies.  IONpath is building the capacity to stain, image and analyze over 15,000 highly multiplexed slides a year by the end of 2020.  The company hopes to unlock valuable data about co-expression levels, proximity of cell populations and correlations to outcomes observed in patients to meaningfully contribute to the development of immunotherapies for partners across industry and academia.  

If you or your company would be interested in learning more about what Research Services can do for your program, please contact us at to talk to our expert team or request a quote.


About IONpath, Inc.
IONpath, Inc. is revolutionizing tissue imaging to accelerate medical discovery and improve human health. The company’s MIBIscope™ System, which utilizes Multiplexed Ion Beam Imaging (MIBI™) technology, represents a transformative step in tissue imaging by simultaneously multiplexing 40+ markers with single cell resolution. Leading research institutes and biotech and pharmaceutical companies are using the MIBIscope in immuno-oncology, immunology and neuroscience research where high-fidelity multiplexed imaging data is needed. In addition to the MIBIscope System IONpath empowers the research and development initiatives of academic, biotech and pharmaceutical partners through IONpath Research Services.

Visit to find out more.

IONpath Announces Commercial Launch of MIBIscope™—the First Multiplexed Ion Beam Imaging System

MIBIscope allows researchers to visualize over 40 biomarkers simultaneously with high resolution, sensitivity, and throughput, and is compatible with standard tissue processing techniques

Menlo Park, Calif., November 5, 2019 – IONpath, Inc., a company revolutionizing multiplexed tissue imaging, launched the MIBIscope™ System, the first commercially available Multiplexed Ion Beam Imaging (MIBI™) system. The MIBIscope enables researchers to image over 40 biomarkers simultaneously at higher sensitivity, resolution, and throughput than existing methods. IONpath is showcasing the platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Maryland from November 6-10.

To help scientists see deeper into the tissue microenvironment and study the relationships between proteins, cells and their environment in intact tissue samples, IONpath has leveraged secondary ion mass spectrometry and elementally labeled antibodies to create MIBI™ technology. This method enables higher throughput than existing multiplexed imaging technologies, such as mass cytometry, and is far more sensitive, permitting single-molecule detection. The MIBIscope can image cellular structures as small as 280 nm and visualize over 40 biomarkers simultaneously with a dynamic range of five orders of magnitude.

“Scientists in oncology and translational research will benefit from the unprecedented insights into spatial relationships within the tissue microenvironment by imaging and characterizing tissue samples at subcellular resolution,” said Harris Fienberg, chief executive officer and co-founder, IONpath. “After successfully piloting the MIBIscope in leading research and biopharma institutions, we are excited to bring the platform to market.”

The MIBIscope System removes only a thin layer of sample during imaging, thus permitting scientists to perform multiple scans on a single sample. Further, by scanning at different levels of depth, researchers can study tissue architecture in three dimensions. The MIBIscope System can be automated to image tissue samples continuously for multiple days, allowing researchers to process hundreds of samples a week and conduct broad cohort studies.

The simple staining process employs a standard immunohistochemistry workflow and is compatible with both FFPE and fresh/frozen tissue. Furthermore, samples are stable for months following staining.

To learn about the MIBIscope, visit IONpath at SITC booth #326, or attend the company’s symposium on Saturday, November 9 at 12:35 pm in Riverview Ballroom A3, where leading researchers from the Dana-Farber Cancer Institute, Stanford University, and University of Colorado, Denver, will be presenting their research using the MIBIscope to characterize the tumor microenvironment. More information about IONpath’s activities at SITC can be found at Information about the MIBIscope System can be found at

About IONpath

IONpath, Inc. is revolutionizing tissue imaging to accelerate discovery for improving human health. The company’s MIBIscope™ System utilizes Multiplexed Ion Beam Imaging (MIBI™) technology, developed at Stanford University, and represents a transformative step forward in molecular pathology. Leading biopharma and biomedical research institutes have been piloting MIBIscope in immuno-oncology, immunology and neuroscience research. MIBIscope is a highly multiplexed imaging platform with unmatched resolution, sensitivity, and throughput—enabling researchers to gain new insights into cellular structure and morphology within tissue.

*For Research Use Only. Not for use in diagnostic procedures.

Media Contact

Press Release: IONpath and Indica Labs establish a co-marketing agreement to promote spatially resolved analysis of tissues imaged with the Multiplexed Ion Beam Imaging (MIBI) System (April 2019)

USA 04/26/2019 – Indica Labs and IONpath announced today that a co-marketing agreement has been established to jointly promote their respective technologies for tissue-based, multiplexed biomarker research.

IONpath’s MIBIscope platform uses secondary ion mass spectrometry (SIMS) to image antibodies tagged with monoisotopic metal reporters, permitting simultaneous visualization of 40+ markers in any tissue type, including FFPE, with unmatched resolution and sensitivity.

“With capacity to measure dozens of proteins with sub-cellular resolution, the MIBIscope platform provides scientists with new insights in understanding cell populations and interactions within the tumor microenvironment” said Harris Fienberg, CEO of IONpath. “We are committed to enable a streamlined workflow from visualization to quantitative data analysis and a partnership with Indica Labs will facilitate our users to integrate HALO with MIBI data for analyses such as cell segmentation and classification,” said Harris Fienberg, CEO of IONpath.

Indica Labs provides image analysis and image management solutions for digital pathology, including HALO, HALO AI and HALO Link.  The HALO platform can analyze an unlimited number of fluorescent biomarkers within the spatial context of the tissue, making it an ideal image analysis solution for immuno-oncology and a natural complement to the multiplexed imaging capabilities provided by the MIBIscope system.

“There is a growing need amongst our customer base for technologies that can facilitate higher multiplexing, especially in the immuno-oncology research area,” said Dr. Kate Lillard Tunstall, CSO of Indica Labs.  “Together, the MIBI technology and HALO platform provide a complete end-to-end solution for multiplexing.  We are excited to work with IONpath to address the needs of our mutual customers.”

About Indica Labs, Inc.

Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO and HALO AI for image analysis and HALO Link to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, respiratory, and toxicological pathology.  For more information, please visit or contact

About IONpath

IONpath™ is a venture-backed, commercial-stage company, founded by Stanford researchers out of the lab of Dr. Garry Nolan, focused on revolutionizing pathology with Multiplexed Ion Beam Imaging (MIBI) technology. MIBI is a multiplexed imaging platform with unmatched resolution, sensitivity, and throughput.   IONpath is headquartered in Menlo Park, CA.

For more information, please visit or contact

Press Release: Journal Cell Features New Immunohistochemistry Imaging Technology from IONpath that Images 40+ Proteins on a Single Slide. (September 6th, 2018)
Paper describes the only multiplexed mass spectrometry imaging technology with unrivaled sensitivity, throughput, and resolution.

Menlo Park, California, Sept. 6th, 2018 — IONpathTM, a venture-backed commercial-stage pathology startup, today announced that a paper detailing the performance of its new Multiplexed Ion Beam Imaging (MIBITM) technology was accepted by the journal Cell and will be featured in the September 6 issue. This study will also be shared during a webinar presented by Dr. Mike Angelo on October 2nd, 2018.

The study leveraged IONpath’s MIBIscopeTM instrument to define tumor and immune cell spatial compositions leading to a discovery of a cell signature that predicts therapeutic response for triple-negative breast cancer.



MIBI technology was invented in Prof. Garry Nolan’s lab and developed by Drs. Sean Bendall and Mike Angelo in the Department of Pathology at Stanford University. MIBI uses secondary-ion mass spectrometry (SIMS), a type of mass spectrometry traditionally used in the semiconductor industry, to image antibodies tagged with monoisotopic metal reporters, permitting 40+ proteins to be simultaneously measured.  

The IONpath MIBIscope platform, coupled with pathologist-validated reagents and downstream image analytics, will enable pathologists and scientists to better understand the complexities of the tissue microenvironment by delivering subcellular resolution, spatial and structural information than previously possible.

The MIBIscope is currently being piloted by top research institutes and biopharmas to enable discoveries in oncology, neuroscience, immunology, microbiology and a number of other fields in which high-fidelity multiplexed imaging data is needed.

In addition, the MIBIscope has been selected as the only highly multiplexed IHC imaging platform for the National Cancer Institutes (NCI) Cancer Immune Monitoring and Analysis Center (CIMAC).

“For the first time, scientists will be able to simultaneously visualize many markers (with 40 plus channels available) on a single FFPE tissue slide with high sensitivity and resolution empowering unique discovery in immuno-oncology research,” said Harris Fienberg, IONpath’s CEO.  



Triple-negative breast cancer (TNBC) is known to be an aggressive and invasive form and represents about 15-20% of all breast cancers. It is generally diagnosed based on the lack of expression of three “receptors” known to fuel most breast cancer tumors: estrogen, progesterone, and HER2‐neu.

While it is known the immune system plays a critical role in cancer progression, getting a comprehensive view of the tumor-immune microenvironment is difficult using current technology. Challenges include autofluorescence, poor resolution resulting in incomplete spatial and contextual information for understanding protein expression within cells in FFPE Tissue.

In this study, Stanford scientists used MIBI technology to comprehensively profile the tumor microenvironment of 41 triple-negative breast cancer patients by simultaneously imaging 36 proteins at a subcellular resolution in diagnostic surgical pathology samples.

By using a multi-step analysis, including cell segmentation, single cell analysis and spatial analysis, the authors revealed how tumor expression and immune composition are interrelated within tissue context, that correlates with overall survival in TNBC. The authors showed how a multiplexed imaging approach can be used to stratify patient populations and identify a unique patient population that will respond to therapy.

“The work by Keren et al highlights the value of characterizing the intact tumor microenvironment with a comprehensive antibody panel and defining meaningful spatial relationships between tumor and infiltrating immune cells. The approach, MIBI-TOF, will be invaluable for analyzing potential mechanisms of immune evasion and responses to immunotherapy in multiple cancers”, said Dr. Margaret Shipp, Professor of Medicine and Director Lymphoma Program, Dana-Farber Cancer Institute.

The MIBI images collected are shared online and can be downloaded through a web-interface MIBItracker software available on the IONpath company website.



MIBI is also currently being used to enable a variety of other applications including applications in neuroscience, where it is ideal for analyzing co-expression of dozens of proteins in brain biopsies (which are problematic for fluorescent-based technology) and autoimmunity where MIBI permits comprehensive analysis of the immune cells involved in the tissue-immune system interface.  Additionally, further work is currently underway to identify biomarkers and stratify patients populations in clinical trials using MIBI.


ABOUT: IONpath™ is a venture-backed, commercial-stage company, founded by Stanford researchers out of the lab of Dr. Garry Nolan, focused on revolutionizing pathology with Multiplexed Ion Beam Imaging (MIBI) technology. MIBI is a multiplexed imaging platform with unmatched resolution, sensitivity, and throughput.   

 Download: IONpath Press Release Cell Publication 09062018

GenomeWeb: IONPath Targeting Immuno-oncology, Pathology With Multiplexed Protein Imaging System

Based on multiplexed ion beam imaging, the system will compete most directly with Fluidigm’s Hyperion imaging mass cytometry platform and, according to IONPath CEO Harris Feinberg, could offer higher levels of speed, sensitivity, and resolution than the Fluidigm system.

Read the full article

Contact Us

We are glad that you prefer to contact us. Please fill our short form and one of our friendly team members will contact you back.

Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther


Contact Us

We are using cookies on our website

Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.